Aurexis® (tefibazumab)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus
Conditions
Staphylococcus Aureus
Trial Timeline
Apr 1, 2005 → Jun 1, 2006
NCT ID
NCT00198289About Aurexis® (tefibazumab)
Aurexis® (tefibazumab) is a phase 2 stage product being developed by Bristol Myers Squibb for Staphylococcus Aureus. The current trial status is completed. This product is registered under clinical trial identifier NCT00198289. Target conditions include Staphylococcus Aureus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00198289 | Phase 2 | Completed |
Competing Products
12 competing products in Staphylococcus Aureus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 77 |
| AZD7760 | AstraZeneca | Phase 1/2 | 41 |
| V710 + Placebo | Merck | Phase 2/3 | 65 |
| Daptomycin | Merck | Phase 2 | 52 |
| Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) | Merck | Phase 2 | 52 |
| Imipenem/cilastatin | Pfizer | Approved | 84 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| blood samples + nasal swabs | Sanofi | Pre-clinical | 22 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |